GlassScriptPhysician profile
Ellen C Cleland
NPI 1124525423
$37,644.26
in general payments reported to CMS, 2019-2025
24 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $98.40 · 2024: $14K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $35K · Food and Beverage: $2,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,357.28 |
| Food and Beverage | $2,286.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $35,405.54 | 2024-2025 | Trintellix |
| Novo Nordisk INC | $547.38 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Xeris Pharmaceuticals, INC. | $290.18 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Axsome Therapeutics, INC. | $168.30 | 2025 | Auvelity |
| Bard Peripheral Vascular, INC. | $145.58 | 2024 | Venovo |
| Otsuka America Pharmaceutical, INC. | $140.27 | 2024-2025 | Rexulti |
| Silk Road Medical, INC. | $136.77 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Amgen INC. | $134.05 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Lilly USA, LLC | $112.11 | 2024 | Mounjaro |
| Abbvie INC. | $111.65 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $90.00 | 2024-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $75.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $61.78 | 2024 | |
| Astellas Pharma US INC | $36.58 | 2023-2025 | Veozah |
| Intra-Sana Laboratories | $31.34 | 2024-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $29.51 | 2025 | Inspire |
| Resmed Corp | $22.71 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.58 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.99 | 2024 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $16.41 | 2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $14.93 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.08 | 2024 | Caplyta |
| Linus Health, INC. | $11.71 | 2024 | Core Cognitive Evaluation |
| Abbott Laboratories | $8.46 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Cleland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.